Drug Profile


Alternative Names: CPV; Cyclopropavir; MBX-400; NSC-D745998; ZSM-I-62

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wayne State University School of Medicine
  • Developer Microbiotix
  • Class Antivirals; Cyclopropanes; Hypoxanthines; Purinones; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cytomegalovirus infections(In volunteers) in USA (PO, Capsule)
  • 04 Jun 2015 National Institute of Allergy and Infectious Diseases plans a phase I trial in Healthy volunteers in USA (NCT02454699)
  • 01 Sep 2012 Microbiotix completes a phase I safety and pharmacokinetics trial in healthy volunteers in USA (NCT01433835)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top